



(51) International Patent Classification:

<i>C07C 23/00</i> (2006.01)	<i>A61P 3/04</i> (2006.01)
<i>C07C 22/00</i> (2006.01)	<i>A61P 3/06</i> (2006.01)
<i>A61K 31/381</i> (2006.01)	<i>A61P 3/08</i> (2006.01)
<i>A61K 31/429</i> (2006.01)	<i>A61P 9/00</i> (2006.01)
<i>A61K 31/11</i> (2006.01)	<i>A61P 9/10</i> (2006.01)
<i>A61K 31/12</i> (2006.01)	<i>A61P 13/00</i> (2006.01)
<i>A61K 31/192</i> (2006.01)	<i>A61P 13/12</i> (2006.01)
<i>A61P 3/02</i> (2006.01)	

(21) International Application Number:

PCT/IB2013/050904

(22) International Filing Date:

3 February 2013 (03.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1835/CHE/2012 10 May 2012 (10.05.2012) IN

(72) Inventor; and

(71) Applicant : **KANDULA, Mahesh** [IN/IN]; Door No. 11-61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME

(57) Abstract: The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout; dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes., obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.



WO 2013/167996 A1